Skip to main content
OpenTrials
Completed

NCT Number: NCT03676816

Self Sampling for Rapid Turnaround Testing in the Emergency Department

Consenting adult female patient felt by the provider to require gonorrhea/chlamydia endocervical testing will be asked to provide an additional self sample specimen. The specimen will be sent to the laboratory using conventional diagnostic test for gonorrhea/chlamydia.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Study protocol:

  • Initial emergency department history and physical examination (standard procedure).

a. Provider identifies patient who is felt to require gonorrhea/chlamydia testing.

i. Provider will contact study staff to consent patient. b. Study staff identifies patient who is felt by provider to require gonorrhea/chlamydia testing. i. Study staff will ask provider if they could move forward with consenting patient.

c. Provider who is study staff identifies patient who is felt to require gonorrhea/chlamydia testing.

  • Study staff will attempt to consent patient.
  • If inclusion criteria are met, and there are no exclusion criteria, written informed consent is obtained.
  • If the patient changes her mind and refuses consent at this point, a notation is written on the front of the research packet, and it is turned in with a refusal notice on the packet.
  • If patient refuses to participate in the self-sampling portion of the study, we will ask patients if they would like to fill out the first half of the patient survey that will contain no personal identification information besides their initials.
  • If patient agrees to participate in the self-sampling, the patient is asked to fill out both page one and page two of the survey after consent is obtained.
  • An attempt is made to write down at least two contact telephone numbers for patients who have given informed consent on page 2 of the patient survey.
  • The patient obtains vaginal self-sample in the restroom/exam room.
  • A preprinted single-use instruction sheet is given to patient detailing sample collection.
  • Vaginal self-sampling collection container has preprinted instructions/requisition and a preprinted label on the Cepheid sample tube to the lab denoting this as research sample.
  • Paper requisition form is also included with the sample which helps with documentation and assigning this sample to be billed to the research study and not to the patient.
  • The patient returns the collection container after obtaining the sample to study staff that consented the patient.
  • The collection container will be sent to the lab via pneumatic tube station.
  • Vaginal self-sampling result is documented in Epic with designation showing differentiation from provider-performed endocervical sampling.
  • Provider-performed endocervical sampling is performed once the patient is assigned a provider and given a private area to conduct a provider-performed endocervical sampling (standard procedure).

a. The collection container is sent to the lab, and the final result is noted in the medical record as per standard practice (standard procedure).

  • Retrospective chart review is performed three days after patient consented in order to obtain provider-performed endocervical sampling results.
  • Patient will be contacted only if there is a false-negative. A positive with either the self-sample or provider collected sample is considered positive, and patient will not be called back about that

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult female emergency department patient felt by the provider to require gonorrhea/chlamydia endocervical testing

Exclusion criteria

  • Non-English speakers with the exception of Spanish speakers (once a Spanish-language informed consent document is approved by the Community Medical Center Institutional Review Board)
  • Prisoner
  • Age <18 years old
  • Active psychiatric condition felt to preclude the ability to give informed consent
  • Treated for gonorrhea/chlamydia within previous four weeks

Treatment and study plan

vaginal self sampling

Procedure

This is a prospective, non-inferiority trial comparing two methods of collection using a US Food and Drug Administration- cleared 90-minute rapid nucleic acid amplification assay, the Xpert CT/NG assay. Any adult female patient admitted to the Emergency Department at Community Regional Medical Center felt by the provider to require gonorrhea/chlamydia endocervical testing may be entered in the study.

Other names: Cepheid, SWAB/A-50

provider-performed endocervical sampling

Procedure

provider-performed endocervical sampling is the gold standard for both gonorrhea and chlamydia. The provider takes a endocervical sample which will get sent to the laboratory as the standard care in comparison to the device being studied.

Primary outcomes

  1. Noninferiority of vaginal self-sampling compared to provider performed endocervical sampling for gonorrhea/chlamydia diagnosis

    Time frame: 2-3 days

    In order for vaginal self-sampling to be considered clinically noninferior to the standard provider-performed endocervical sampling method of collection, we established a minimum sensitivity of 90%. This was based on previous research showing Sexually Transmitted Infection (STI) clinicians' top priority for a point of care STI test is a minimum sensitivity of 90%. In addition, a previous ED study examining urine gonorrhea/chlamydia diagnosis using the same point of care test as this study also used a minimum sensitivity of 90%. (9) Thus, our primary outcome measure was examining for the noninferiority of VSS sensitivity for gonorrhea/chlamydia, with noninferiority being demonstrated if the sensitivity is >=90%.

Secondary outcomes

  1. Predictive value

    Time frame: 2-3 days

    Vaginal self-sampling specificity, positive predictive value, negative productive value for gonorrhea/chlamydia (measured by individual patient)

  2. Predictive value-Gonorrhea

    Time frame: 2-3 days

    Vaginal self-sampling sensitivity, specificity, positive predictive value, negative predictive value for gonorrhea

  3. Predictive value-Chlamydia

    Time frame: 2-3 days

    Vaginal self-sampling sensitivity, specificity, positive predictive value, negative predictive value for chlamydia

  4. Demographics

    Time frame: 2-3 days

    Concordance of vaginal self-sampling to provider-performed endocervical sampling

  5. Percentage

    Time frame: 2-3 days

    Acceptance rate vaginal self-sample

  6. Rate-Worried

    Time frame: 2-3 days

    Rate of patients worried about doing vaginal self-sampling and correctly

  7. Rate-Prefer

    Time frame: 2-3 days

    Rate of patients that prefer vaginal self-sample to provider-performed endocervical sampling

  8. Numeric

    Time frame: 2-3 days

    Number of patients that refused vaginal self-sampling

  9. Descriptive

    Time frame: 2-3 days

    Description of reasons for refusal of vaginal self-sampling

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • Central California Faculty Medical Group

Registry information

Official study title

Vaginal Self-sampling for Rapid Turnaround Gonorrhea/Chlamydia Testing in the Emergency Department

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Sep 19, 2018
Registry last updated
Aug 5, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.